Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

A Lifetime on the Hips: Programming Lower-Body Fat to Protect Against Metabolic Disease

  1. Michael M. Swarbrick⇑
  1. Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia, and School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia
  1. Corresponding author: Michael M. Swarbrick, m.swarbrick{at}garvan.org.au.
Diabetes 2014 Nov; 63(11): 3575-3577. https://doi.org/10.2337/db14-1085
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In the 60 years since Vague (1) described that an “android” pattern of adipose tissue (AT) distribution was associated with diabetes, atherosclerosis, gout, and kidney stones, many of the physiological mechanisms underlying this relationship have been illuminated. To date, most of the effort has been directed at understanding how accumulation of intra-abdominal fat, also known as visceral AT (VAT), promotes insulin resistance (IR). IR is the common defect underlying glucose intolerance, central obesity, dyslipidemia, and hypertension. This phenotypic cluster, called the metabolic syndrome, is associated with a doubling of cardiovascular disease risk and a fivefold increased risk of type 2 diabetes (2).

VAT is likely to promote IR in several ways. Enlarged adipocytes in VAT were originally thought to promote hepatic, and eventually systemic, IR via increased portal free fatty acid (FFA) flux (3). Other factors are likely to be involved, however, because although FFA flux from VAT does increase in obesity, it is not the major determinant of portal FFA concentrations (4). In obesity, VAT also may contribute to IR via alterations in its secreted products (adipokines), as well as proinflammatory molecules such as tumor necrosis factor-α, interleukin-6 (IL-6), C-reactive protein (CRP), and monocyte chemoattractant protein-1 (MCP-1) (5).

Independently of VAT, parallel studies have established that a gynoid pattern of AT distribution, characterized by greater amounts of subcutaneous AT (SAT) in the lower body, is associated with improved glucose tolerance and lipid profile and that this fat pattern may protect against cardiovascular disease (6,7). These protective effects often vary with sex, but they are well supported by population-based studies using simple anthropometry (8). Taken together, a large body of research shows that VAT and lower-body SAT exert opposing influences on the risk of metabolic disease in humans.

How does lower-body SAT protect against metabolic disease? In women with lower-body obesity, gluteal SAT (GSAT) takes up more meal-related fatty acids than in either upper-body obese women or men (9). GSAT is thought to function as a “metabolic sink,” protecting nonadipose tissues from excessive FFA exposure and development of IR (10). Once sequestered in GSAT, these lipids are relatively more resistant to mobilization than when they are stored in other depots (11). Compared with VAT and abdominal SAT (ASAT), GSAT also produces greater amounts of palmitoleate, a lipid-signaling molecule that improves insulin action in liver and skeletal muscle (12).

Many key studies on GSAT have been performed by Fredrik Karpe, Keith Frayn, and colleagues at the University of Oxford (reviewed in 13). In this issue of Diabetes, these investigators extend their previous work by studying relationships between regional adiposity (measured by DEXA), IR (by HOMA-IR), and fasting plasma concentrations of insulin, triglycerides, HDL cholesterol, and CRP. Notably, the new study was conducted in a sample of 3,399 healthy adults (14). When overall adiposity was accounted for, the amount of GSAT in both males and females was negatively associated with fasting insulin, IR, and dyslipidemia. In males, GSAT was negatively associated with CRP concentrations. As in other studies (15), ASAT mass was positively correlated with both IR and dyslipidemia.

To further investigate the protective effects of GSAT, transcriptomic analysis was performed in paired samples of GSAT and ASAT, an approach that revealed marked differences in developmental gene expression, particularly of Homeobox (HOX) genes. The most differentially expressed genes were HOXA5 (higher in ASAT) and the long noncoding RNA HOTAIR (higher in GSAT), which is known to repress transcription of HOXD genes via chromatin remodeling (16). When all of the differentially expressed genes were grouped using gene ontology, four sets of genes were downregulated in GSAT: Two sets were related to sequence-specific DNA binding, one was related to morphogenesis, and the last was related to pattern specification.

Immortalized preadipocytes grown and differentiated in culture maintain intrinsic properties such as replication, adipogenesis, and susceptibility to apoptosis that are determined by their depot of origin (17). In the newly published report, Pinnick et al. (14) refined the concept of depot-specific transcriptional “memory” by identifying differences in gene expression between ASAT and GSAT (sequence-specific DNA binding genes such as HOXA5, HOTAIR, IRX2, TBX5, HOXA6, HOXC11, and SHOX2) that persisted in adipocytes differentiated in vitro (Fig. 1). Examination of the promoter regions of two genes, TBX5 and HOTAIR, revealed depot-specific patterns of DNA methylation that were consistent with altered expression. In adipocytes derived from ASAT, knockdown of TBX5 (which was normally more highly expressed in ASAT than GSAT) reduced cellular proliferation, lipid content, and expression of mature adipocyte genes. Greater understanding of these depot-specific factors may allow us to manipulate regional adiposity and, in turn, influence an individual’s risk of obesity-related metabolic diseases.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

A depot-specific transcriptional “memory” contributes to the opposing effects of GSAT and ASAT depots on metabolism. Independently of total fat mass, GSAT and ASAT masses display opposing relationships with fasting insulinemia, insulin resistance, and dyslipidemia (gluteal, beneficial; abdominal, detrimental). Pinnick et al. (14) identify depot-specific gene expression signatures in a number of developmental genes (increased expression of HOTAIR, SHOX2, and HOXC11 in GSAT and HOXA5, IRX2, TBX5, and HOXA6 in ASAT) that are maintained in preadipocytes isolated from these depots and in mature adipocytes differentiated in vitro. In obesity, these intrinsic differences between depots are thought to enable GSAT to resist many of the deleterious changes in gene expression (inflammation and hypometabolism) that occur in ASAT. Arteriovenous measurements from these depots revealed that ASAT secreted more than four times as much proinflammatory IL-6 as GSAT, despite comparable leptin production and adipocyte size distribution.

The pathways by which GSAT confers its protective effects also are explored in the current study by correlating gene expression with individual metabolic syndrome components. In both GSAT and ASAT, obesity was positively associated with inflammatory gene expression, while being negatively associated with energy-generating gene expression. Notably, these relationships were much stronger in ASAT, which led the authors to conclude that in obesity GSAT may resist the shift toward a proinflammatory, hypometabolic state. Similarly, measurements of arteriovenous differences in cytokine concentrations in ASAT and GSAT showed that despite comparable adipocyte size distribution and leptin production, ASAT released more than four times as much proinflammatory IL-6 per gram of tissue and tended to produce more MCP-1. A variety of AT-immune cells (macrophages, T cells, B cells) have been implicated in the pathogenesis of IR, and all of them can produce IL-6. Immune cell profiling of ASAT and GSAT in this study might have revealed the major source of IL-6 in ASAT. Further studies are certainly warranted.

The study by Pinnick et al. (14) adds considerably to our understanding of how AT distribution influences metabolism. Determining how GSAT resists metabolic dysfunction in obesity may reveal new therapeutic targets for glucose intolerance, IR, and dyslipidemia. In individuals with android obesity or partial lipodystrophy, for example, a selective expansion of GSAT could divert lipids away from deleterious AT depots, sparing liver and skeletal muscle from lipotoxicity. This idea is reminiscent of the hyperplasia in SAT observed following thiazolidinedione treatment (18) and in transgenic ob/ob mice overexpressing adiponectin (19). Similarly, intra-abdominal transplantation of SAT, but not VAT, prevents high-fat diet–induced inflammation and glucose intolerance in mice (20). Diverting energy into GSAT therefore could improve metabolism, possibly giving a positive meaning to the old saying: “A moment on the lips, a lifetime on the hips.”

Article Information

Acknowledgments. The author thanks Amanda Brandon, Paul Lee, and Rebecca Stewart (Garvan Institute) for their constructive comments on the manuscript.

Funding. M.M.S. is supported by a project grant from the National Health and Medical Research Council of Australia (APP1031769).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 3785.

  • © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Vague J
    . The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4:20–34pmid:13282851
    OpenUrlAbstract
  2. ↵
    1. Cornier MA,
    2. Dabelea D,
    3. Hernandez TL,
    4. et al
    . The metabolic syndrome. Endocr Rev 2008;29:777–822pmid:18971485
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Björntorp P
    . “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990;10:493–496pmid:2196039
    OpenUrlFREE Full Text
  4. ↵
    1. Nielsen S,
    2. Guo Z,
    3. Johnson CM,
    4. Hensrud DD,
    5. Jensen MD
    . Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582–1588pmid:15173884
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Ouchi N,
    2. Parker JL,
    3. Lugus JJ,
    4. Walsh K
    . Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85–97pmid:21252989
    OpenUrlCrossRefPubMed
  6. ↵
    1. Snijder MB,
    2. Dekker JM,
    3. Visser M,
    4. et al.,
    5. Hoorn Study
    . Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn Study. Diabetes Care 2004;27:372–377pmid:14747216
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Okura T,
    2. Nakata Y,
    3. Yamabuki K,
    4. Tanaka K
    . Regional body composition changes exhibit opposing effects on coronary heart disease risk factors. Arterioscler Thromb Vasc Biol 2004;24:923–929pmid:15016639
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Snijder MB,
    2. Zimmet PZ,
    3. Visser M,
    4. Dekker JM,
    5. Seidell JC,
    6. Shaw JE
    . Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 2004;28:402–409pmid:14724659
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Santosa S,
    2. Hensrud DD,
    3. Votruba SB,
    4. Jensen MD
    . The influence of sex and obesity phenotype on meal fatty acid metabolism before and after weight loss. Am J Clin Nutr 2008;88:1134–1141pmid:18842804
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lemieux I
    . Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Biol 2004;24:795–797pmid:15132969
    OpenUrlFREE Full Text
  11. ↵
    1. Goodpaster BH,
    2. Kelley DE,
    3. Wing RR,
    4. Meier A,
    5. Thaete FL
    . Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999;48:839–847pmid:10102702
    OpenUrlAbstract
  12. ↵
    1. Pinnick KE,
    2. Neville MJ,
    3. Fielding BA,
    4. Frayn KN,
    5. Karpe F,
    6. Hodson L
    . Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. Diabetes 2012;61:1399–1403pmid:22492525
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Manolopoulos KN,
    2. Karpe F,
    3. Frayn KN
    . Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010;34:949–959pmid:20065965
    OpenUrlCrossRefPubMed
  14. ↵
    1. Pinnick KE,
    2. Nicholson G,
    3. Manolopoulos KN,
    4. et al.,
    5. the MolPAGE Consortium
    . Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014;63:3785–3797pmid:24947352
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Fox CS,
    2. Massaro JM,
    3. Hoffmann U,
    4. et al
    . Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39–48pmid:17576866
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Rinn JL,
    2. Kertesz M,
    3. Wang JK,
    4. et al
    . Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007;129:1311–1323pmid:17604720
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Tchkonia T,
    2. Giorgadze N,
    3. Pirtskhalava T,
    4. et al
    . Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes 2006;55:2571–2578pmid:16936206
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Miyazaki Y,
    2. Mahankali A,
    3. Matsuda M,
    4. et al
    . Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784–2791pmid:12050251
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Kim JY,
    2. van de Wall E,
    3. Laplante M,
    4. et al
    . Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621–2637pmid:17717599
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Hocking SL, Stewart RL, Brandon AE, et al. Intra-abdominal transplantation of subcutaneous adipose tissue in mice prevents high-fat diet-induced inflammation and glucose intolerance (Abstract). Diabetes 2014;63(Supp. 1):A435
View Abstract
PreviousNext
Back to top
Diabetes: 63 (11)

In this Issue

November 2014, 63(11)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Lifetime on the Hips: Programming Lower-Body Fat to Protect Against Metabolic Disease
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Lifetime on the Hips: Programming Lower-Body Fat to Protect Against Metabolic Disease
Michael M. Swarbrick
Diabetes Nov 2014, 63 (11) 3575-3577; DOI: 10.2337/db14-1085

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

A Lifetime on the Hips: Programming Lower-Body Fat to Protect Against Metabolic Disease
Michael M. Swarbrick
Diabetes Nov 2014, 63 (11) 3575-3577; DOI: 10.2337/db14-1085
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.